This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Simvastatin in Colorectal Surgery (StatCol)

This study has been completed.
Counties Manukau Health
Waitemata District Health Board
Auckland District Health Board
Information provided by (Responsible Party):
Andrew G Hill, University of Auckland, New Zealand Identifier:
First received: October 13, 2009
Last updated: November 27, 2013
Last verified: November 2013

Statins (HMG-CoA reductase inhibitors) are a widely used class of cholesterol-lowering drugs that have an established role in the medical management of cardiovascular disease. Their benefits have also been shown in the surgical setting with decreased cardiovascular complications and lower perioperative mortality following cardiac and vascular surgery. There is now considerable evidence showing statins have useful pleiotropic properties that extend beyond cholesterol lowering, including anti-inflammatory, anti-oxidant, immunomodulatory and fibrinolytic effects. Growing evidence suggests these effects may be useful in attenuating the proinflammatory and metabolic stress response to surgery and the benefit of statins may extend to other surgical settings such as abdominal surgery.

Laboratory studies demonstrate the surgically-relevant benefits of statins and show they decrease peritoneal inflammation, reduce the severity of intestinal ischaemia-reperfusion injury, improve survival in models of abdominal sepsis, decrease the formation of postoperative intraperitoneal adhesions and improve the healing of colonic anastomoses. Retrospective clinical studies show statins improve outcomes in sepsis, reduce the postoperative systemic inflammatory response syndrome (SIRS) and are associated with decreased rates of surgical wound infections and postoperative respiratory complications following various non-cardiac general surgical procedures. However, no prospective studies have specifically evaluated the perioperative use of statins in abdominal surgery. Using colorectal surgery as a model for major abdominal surgery, the investigators will conduct a randomised controlled trial evaluating the effect of perioperative statin use on postoperative morbidity, local and systemic inflammatory response, and functional recovery after surgery.

Condition Intervention Phase
Intestinal Neoplasm Perioperative Care Drug: Simvastatin Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Prospective, Double-Blinded, Multi-Centred, Randomised Controlled Trial of Perioperative Simvastatin Use in Elective Colorectal Surgery

Resource links provided by NLM:

Further study details as provided by Andrew G Hill, University of Auckland, New Zealand:

Primary Outcome Measures:
  • Total complications [ Time Frame: Up to post-operative day 30 ]
    Complications pre-defined and graded by the Clavien-Dindo classification

Secondary Outcome Measures:
  • Peritoneal Cytokines [ Time Frame: Postoperative Day 1 ]
  • Serum cytokines [ Time Frame: Post-operative Day 1 ]
  • Change in serum C-reactive protein (CRP) [ Time Frame: Baseline and Postoperative Day 1, 2 and 3 ]
  • Change in functional recovery [ Time Frame: Baseline and Postoperative Day 1, 3, 7, 14, and 30 ]

Enrollment: 132
Study Start Date: October 2011
Study Completion Date: September 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo tablets (Inert calcium lactate)
Drug: Placebo
Placebo (Inert calcium lactate) tablets 3-7 days pre-op to 14 days post-op (as per experimental arm)
Experimental: Simvastatin
40mg of Simvastatin given 3-7 days pre-op and continued till 14 days post-op
Drug: Simvastatin
40mg orally, given 3-7 days pre-op and continued till 14 days post-op


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Consecutive consenting patients undergoing elective colectomy, rectal resection, and reversal of Hartmann's procedure at Middlemore Hospital, Manukau Surgery Centre, Auckland City Hospital, and North Shore Hospital.

Exclusion criteria:

  • Acute presentation
  • Already taking statins or other lipid-lowering medication
  • Known adverse reaction to statins
  • Hepatic dysfunction
  • Moderate to severe renal dysfunction
  • Previous history of rhabdomyolysis
  • On contraindicated medication
  • Pregnancy
  • Breastfeeding
  • Patient choice.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00994903

New Zealand
Auckland City Hospital
Auckland, New Zealand
Manukau Surgical Centre, Middlemore Hospital
Auckland, New Zealand
North Shore Hospital
Auckland, New Zealand
Sponsors and Collaborators
University of Auckland, New Zealand
Counties Manukau Health
Waitemata District Health Board
Auckland District Health Board
Principal Investigator: Andrew G Hill, MBChB MD FRACS University of Auckland, New Zealand
  More Information

Responsible Party: Andrew G Hill, Professor Andrew Hill, University of Auckland, New Zealand Identifier: NCT00994903     History of Changes
Other Study ID Numbers: StatCol
Study First Received: October 13, 2009
Last Updated: November 27, 2013

Keywords provided by Andrew G Hill, University of Auckland, New Zealand:
Intestinal Neoplasms
Perioperative Care

Additional relevant MeSH terms:
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors processed this record on August 16, 2017